noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5
Peakequity Partners Management Co LLC

Thoma Bravo Completes Strategic Investment in PeakEquity Portfolio[...]
Peakequity Partners Management Co LLC

HighLevel Announces Minority Growth Investment from General Atlantic

Healthcare

Pappas Capital LLC

04/14/2015 | Press release | Archived content

Envisia Therapeutics Names Dr. Rhett Schiffman Chief Medical Officer

News | 04. 14. 2015

Envisia Therapeutics

RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology.

Pappas Capital LLC published this content on April 14, 2015, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format